Designing a care pathway for high risk parkinson’s patients
dc.contributor.author | Chloe, TLY | |
dc.contributor.author | Dominey, T | |
dc.contributor.author | Pearson, E | |
dc.contributor.author | Murphy, F | |
dc.contributor.author | Carroll, C | |
dc.date.accessioned | 2019-02-07T15:55:35Z | |
dc.date.available | 2019-02-07T15:55:35Z | |
dc.date.issued | 2018-10 | |
dc.identifier.uri | http://hdl.handle.net/10026.1/13277 | |
dc.description.abstract |
<jats:sec><jats:title>Objective</jats:title><jats:p>To inform pathway design for patients at high risk of an adverse outcome at 5 years post-Parkinson’s disease (PD) diagnosis.</jats:p></jats:sec><jats:sec><jats:title>Background</jats:title><jats:p>In our service, all newly diagnosed patients follow a 12 month new patient pathway, which includes assessment with PDQ-39, NMS Quest and MOCA. Use of a prognostic calculator<jats:sup>1</jats:sup> allows for refinement of the pathway according to patient need. Patients are classified as low (0–0.3), medium (0.31–0.79) or high (0.8–1) risk of an adverse outcome at 5 years (postural instability, dementia, death).</jats:p></jats:sec><jats:sec><jats:title>Aim</jats:title><jats:p>We aim to evaluate whether assessments in the newly diagnosed pathway identify additional care needs in higher risk patients.</jats:p></jats:sec><jats:sec><jats:title>Methods</jats:title><jats:p>An evaluation was carried out of our new patient database. Individuals who had the prognostic indicator performed (n=52) were included in the evaluation.</jats:p></jats:sec><jats:sec><jats:title>Results</jats:title><jats:p>Patients in the high risk groups were found to be older and more cognitively impaired than lower risk patients (p<0.05). MOCA scores negatively correlated with NMS Quest (r=−0.44, p<0.001) and PDQ-39 (r=−0.51, p<0.001) suggesting as cognition becomes impaired, NMS burden increases, and quality of life is reduced.</jats:p></jats:sec><jats:sec><jats:title>Conclusions</jats:title><jats:p>Additional care needs were identified in high-risk patients. These findings highlight additional resources are required in this patient cohort to ensure needs are met.</jats:p></jats:sec><jats:sec><jats:title>Reference</jats:title><jats:list list-type="order"><jats:list-item><jats:p>. Velseboer DC, et al. Development and external validation of a prognostic model in newly diagnosed Parkinson disease.</jats:p></jats:list-item></jats:list></jats:sec> | |
dc.language.iso | en | |
dc.subject | 32 Biomedical and Clinical Sciences | |
dc.subject | 3209 Neurosciences | |
dc.subject | 3202 Clinical Sciences | |
dc.subject | Prevention | |
dc.subject | Neurodegenerative | |
dc.subject | Patient Safety | |
dc.subject | Clinical Research | |
dc.subject | Parkinson's Disease | |
dc.subject | Neurosciences | |
dc.subject | Brain Disorders | |
dc.subject | Acquired Cognitive Impairment | |
dc.subject | Aging | |
dc.subject | 7.1 Individual care needs | |
dc.subject | 7 Management of diseases and conditions | |
dc.subject | Neurological | |
dc.title | Designing a care pathway for high risk parkinson’s patients | |
dc.type | presentation | |
plymouth.author-url | https://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000449016200054&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=11bb513d99f797142bcfeffcc58ea008 | |
dc.identifier.doi | 10.1136/jnnp-2018-abn.53 | |
plymouth.organisational-group | /Plymouth | |
plymouth.organisational-group | /Plymouth/Faculty of Health | |
plymouth.organisational-group | /Plymouth/REF 2021 Researchers by UoA | |
plymouth.organisational-group | /Plymouth/REF 2021 Researchers by UoA/UoA03 Allied Health Professions, Dentistry, Nursing and Pharmacy | |
plymouth.organisational-group | /Plymouth/Research Groups | |
plymouth.organisational-group | /Plymouth/Research Groups/FoH - Applied Parkinson's Research | |
plymouth.organisational-group | /Plymouth/Research Groups/FoH - Community and Primary Care | |
plymouth.organisational-group | /Plymouth/Research Groups/Institute of Translational and Stratified Medicine (ITSMED) | |
plymouth.organisational-group | /Plymouth/Research Groups/Institute of Translational and Stratified Medicine (ITSMED)/CCT&PS | |
plymouth.organisational-group | /Plymouth/Research Groups/Plymouth Institute of Health and Care Research (PIHR) | |
plymouth.organisational-group | /Plymouth/Users by role | |
plymouth.organisational-group | /Plymouth/Users by role/Academics | |
dc.publisher.place | Association of British Neurologists 2018 Meeting | |
dc.rights.embargoperiod | Not known | |
rioxxterms.versionofrecord | 10.1136/jnnp-2018-abn.53 | |
rioxxterms.licenseref.uri | http://www.rioxx.net/licenses/all-rights-reserved | |
rioxxterms.type | Other |